Dr Ching Ching Leow | AVP, Immuno-Oncology Clinical Development
Eli Lilly and Company

Dr Ching Ching Leow, AVP, Immuno-Oncology Clinical Development, Eli Lilly and Company

Dr. Ching Ching Leow joined the Immuno-Oncology Clinical Development team at Lilly in January 2017 responsible for clinical development for a number of immunooncology programs. From 2008 to 2016 that she was a Medical Scientist and Translational lead at AstraZeneca responsible for conception and execution of translational medicine plans for novel immunooncology targets, such as OX40 and CD73. Earlier experiences included target discovery and pharmacology at MedImmune and post-doctoral fellowship at Genentech. Dr. Leow obtained her PhD in Molecular Medicine and Genetics at the University of Toronto.


DC Co-conference Day 2 April 4 @ 09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

  • Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40
  • Understanding the pathways used to create immune suppression and techniques to slow down immune suppression
  • What makes t-cell agonists so hard to work with vs checkpoint inhibitors?

back to speakers